Opinion
Video
Author(s):
A panelist discusses how novel targeted therapies such as antibody-drug conjugates are rapidly evolving in gynecologic oncology, with multiple agents targeting different biomarkers in development, though optimal sequencing strategies remain to be determined.
Video content is prompted by the following:
Novel Targeted Therapies in the Treatment Landscape
Key Themes:
Notable Insights:
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.